A 5-aminosalicylic acid (5-ASA) agent used as first-line therapy for induction and maintenance of remission in mild-to-moderate ulcerative colitis. Mesalamine acts locally on the colonic mucosa and is available in multiple formulations designed to deliver the active drug to specific segments of the GI tract.
Colorectal cancer risk reduction in ulcerative colitis patients2,4
What to watch for
Headache
Nausea
Abdominal pain
Known hypersensitivity to mesalamine, salicylates, or any component1,2
Severe renal impairment
The bottom line
Evidence rating strong. Most-documented uses: induction of remission in mild-to-moderate ulcerative colitis, maintenance of remission in ulcerative colitis, reduction of mucosal inflammation. 10 sources indexed (2004–2025), with 3 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Exerts a topical anti-inflammatory effect on the colonic epithelium through multiple mechanisms: inhibition of cyclooxygenase (COX) and lipoxygenase pathways (reducing prostaglandin and leukotriene synthesis), scavenging of reactive oxygen species, inhibition of NF-kB nuclear translocation, and modulation of mucosal immune cell function. The exact mechanism is not fully elucidated.
Class
Aminosalicylate (IBD)
Absorption
Water-soluble; take with food
Dosing
Dosing & protocol.
Common range
2.4–4.8 g/day in divided doses (oral); 1–4 g/day (rectal) (as prescribed by your physician)
Recommended form
Delayed-release tablet, extended-release capsule, rectal suppository, or enema
Some formulations should be taken with food for consistent drug release; swallow tablets whole, do not break the outer coating
Safety
Full safety detail.
Side effects
Headache
Nausea
Abdominal pain
Diarrhea
Flatulence
Nephrotoxicity (rare; interstitial nephritis)
Pancreatitis (rare)
Contraindications
Known hypersensitivity to mesalamine, salicylates, or any component1,2
Severe renal impairment
Patients with salicylate allergy
Caution in patients with pre-existing renal disease3,5
Curcumin has randomized-trial and meta-analysis evidence as an adjunct to mesalamine in mild-to-moderate ulcerative colitis. Higher-dose curcumin added to optimized mesalamine improved clinical and endoscopic remission in one trial, while low-dose curcumin was not effective in another. Benefits depend on dose, formulation, adherence, and disease severity.
Recommendation: Do not replace mesalamine with curcumin. If adding curcumin, use it consistently and keep your mesalamine dose unchanged unless your gastroenterologist changes it. Stop and seek care for worsening bleeding, fever, severe pain, or dehydration.
Multi-strain probiotics have been studied as add-ons to 5-ASA therapy, including mesalamine, in ulcerative colitis. Trials of VSL#3-type preparations showed improved disease activity scores or remission outcomes in some patients, though probiotic strains and doses matter. This is most relevant for mild-to-moderate disease and remission support.
Recommendation: Use probiotics as an adjunct, not as a substitute for mesalamine. Choose a product with studied strains and an adequate dose, and reassess symptoms after 8 to 12 weeks. Avoid probiotic use without medical input if you are severely immunocompromised or have a central venous catheter.
Saccharomyces boulardii has limited human evidence as an add-on during mesalamine maintenance for mild-to-moderate ulcerative colitis flare symptoms. A small pilot trial reported clinical remission in many completers, but controlled confirmation is limited. Treat this as an emerging adjunct, not a core ulcerative colitis therapy.
Recommendation: If you try Saccharomyces boulardii with mesalamine, keep your prescription regimen unchanged and reassess after about 4 to 8 weeks. Avoid it if you are severely immunocompromised, critically ill, or have a central venous catheter because rare bloodstream infections have been reported with probiotic yeasts.
Malik A, Goyal H, Adler DG et al.. Budesonide Versus Mesalamine in Microscopic Colitis: A Comparative Meta-analysis of Randomized Controlled Trials. Journal of clinical gastroenterology. 2025
Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Current medical research and opinion. 2021
Iannone A, Ruospo M, Wong G et al.. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials. Canadian journal of gastroenterology & hepatology. 2018
Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2004
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Mesalamine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack